JCJacob D. Cohen

Jacob D. Cohen

*This is an algorithmically generated author record based on publicly available information.

Jacob D. Cohen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Spherical Nucleic Acids: Turning Synthetic Advances and Fundamental Discovery into Translational Breakthroughs in Chemistry, Materials Development, Biology, and Medicine

    by Connor M. Forsyth, Rachel R. Chan, Tanner D. Fink, Janice Kang, Jacob D. Cohen, Sarah Hurst Petrosko, Chad A. Mirkin

    ConspectusEarly research in nanoscience and nanotechnology focused on gaining synthetic control over the size, shape, and composition of nanostructures, as well as exploring their fundamental properties. Over the past few decades, these capabilities have become increasingly sophisticated. Today, we have well-established synthetic toolkits and methodologies that enable the design of nanostructures with tailored properties and functions, guided by sets of design rules, for use in many areas spanning biology and medicine to energy, the environment, and catalysis.To illustrate this paradigm, where synthesis and fundamental discovery drive engineering and technological innovation, we examine spherical nucleic acids (SNAs) as a case study. SNAs are nanoconstructs consisting of a nanoparticle core densely functionalized with a radially oriented oligonucleotide shell. Over the past 30 years, the evolution of SNAs has spanned their invention, the development of increasingly advanced syntheses enabling the creation of dozens of SNA classes (and related DNA-functionalized anisotropic materials, often termed programmable atom equivalents [PAEs]), the discovery of novel phenomena that have reshaped core chemical principles, and their translation into nanomedicines, biological labels, and synthons in materials science.SNAs were first developed in 1996 as gold nanoparticle-DNA conjugates. Since then, extensive study has revealed common structural features that are tied to their unique properties, defining SNAs as a distinct materials class. Most SNAs feature a core (typically a nanoparticle, though recent advances involve molecular scaffolds) that concentrate nucleic acid strands into close proximity. This architecture confers several distinctive properties: enhanced binding affinity to complementary DNA (both free and surface-bound), resistance to enzymatic degradation, reduced immune activation (unless specifically designed for immunostimulation), and efficient cellular uptake without requiring transfection agents.These synthetic and fundamental advances offer significant advantages in biomedical probe and therapeutic design. Due to their modularity, stability, biocompatibility, and ability to access intracellular compartments, SNAs have been applied as intracellular and extracellular probes, tools for gene regulation, vaccines, and gene editing platforms (especially when coupled with CRISPR/Cas9 technology). In parallel, SNAs serve as foundational elements in a new class of programmable matter: DNA-mediated colloidal crystals. Here, sequence-specific DNA interactions are used to organize SNAs into three-dimensional, periodic structures. This line of inquiry has enabled the design and synthesis of thousands of crystal variations, with different lattice symmetries, parameters, and nanoparticle compositions, unlocking the potential for novel optical and mechanical metamaterials and catalysts with exceptional properties, such as negative refractive indices, shape memory, and second harmonic generation. In sum, SNAs exemplify how synthetic mastery and fundamental discovery can catalyze innovation across disciplines, providing a framework that chemists can use in developing transformative new materials.


  • Open Access

    The Immunopathobiology of SARS-CoV-2 Infection

    by Milankumar Patel, Farah Shahjin, Jacob D Cohen, Mahmudul Hasan, Jatin Machhi, Heerak Chugh, Snigdha Singh, Srijanee Das, Tanmay A Kulkarni, Jonathan Herskovitz, et al.

    Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to coronavirus disease 2019 (COVID-19). Virus-specific immunity controls infection, transmission and disease severity. With respect to disease severity, a spectrum of clinical outcomes occur associated with age, genetics, comorbidities and immune responses in an infected person. Dysfunctions in innate and adaptive immunity commonly follow viral infection. These are heralded by altered innate mononuclear phagocyte differentiation, activation, intracellular killing and adaptive memory, effector, and regulatory T cell responses. All of such affect viral clearance and the progression of end-organ disease. Failures to produce effective controlled antiviral immunity leads to life-threatening end-organ disease that is typified by the acute respiratory distress syndrome. The most effective means to contain SARS-CoV-2 infection is by vaccination. While an arsenal of immunomodulators were developed for control of viral infection and subsequent COVID-19 disease, further research is required to enable therapeutic implementation.


  • Open Access

    Exonic Disruption Facilitates Antiviral CRISPR-Cas9 Activity for Multistrain HIV-1 Elimination

    by Jonathan Herskovitz, Mahmudul Hasan, Milankumar Patel, Wilson R. Blomberg, Jacob D. Cohen, Jatin Machhi, Daniel Stein, Evan A. Schroder, JoEllyn McMillan, Channabasavaiah B. Gurumurthy, et al.

    A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+ leukocytes. The high mutation rate of HIV-1 gives rise to numerous circulating strains with increased capacity for immune evasion and antiretroviral drug resistance. To facilitate viral elimination while accounting for this diversity, we propose genetic inactivation of proviral DNA with CRISPR-spCas9. We designed a library of “mosaic gRNAs” against a HIV-1 consensus sequence constructed from 4004 clinical strains, targeting the viral transcriptional regulator tat. Testing in 7 HIV-1 transmitted founder strains led, on average, to viral reductions of 82% with tandem TatD and TatE (TatDE) treatment. No off-target cleavages were recorded. Lentiviral transduction of TatDE attenuated latency reversal by 94% in HIV-infected, transcriptionally silent ACH2 T cells. In all, TatDE guide RNAs successfully disrupted 5 separate HIV-1 exons ( tat 1-2 / rev 1-2 / gp41 ) providing a pathway for CRISPR-directed HIV-1 cure therapies. Significance Statement: Over 38 million individuals worldwide are infected with HIV-1, which necessitates lifelong dependence on antiretroviral therapy (ART) to prevent viral replication that leads to AIDS. Efforts to rid hosts of HIV-1 are limited by the virus’ abilities to integrate proviral DNA in nuclei, mutate their genomes, and lay dormant for decades during ART treatment. We developed mosaic guide RNAs, TatD and TatE, for CRISPR-Cas9 that recognize the majority of known HIV-1 strains and inactivate 94% of proviral DNA in latently infected cells. Tandem TatDE-CRISPR inactivation of 5 viral exons (t at 1-2 , rev 1-2 , and gp41 ), which blocked HIV-1 replication for 28 days in CD4+ T cells without unwanted editing to the host genome, may serve as a viable strategy for HIV cure.